anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Isolates should be tested using amoxicillin/clavulanic acid and the following criteria should be used:

Note: These interpretive criteria are based on the recommended doses for respiratory tract infections. 

A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration usually achievable. A report of “Intermediate” indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Standardized susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures. Standard amoxicillin/clavulanate potassium powder should provide the following MIC values: 

††Expressed as concentration of amoxicillin in the presence of clavulanic acid at a constant 2 parts amoxicillin to 1 part clavulanic acid.
A computer-implemented method includes receiving a group of sets. Each set has values for immutable attributes that match values for at least one mutable attribute in a prediction request. The method includes generating a deviation model based on the group of sets. The method includes generating multiple sets of likely mutable attribute values using the deviation model. The method includes automatically selecting a neural network based on at least one of the likely mutable attribute values. The neural network includes a set of layers. Each layer includes a set of nodes. A first layer receives inputs at the set of nodes of the input layer. A last layer outputs, from the neural network, outputs modified by a preceding layer. The method includes generating a likelihood corresponding to the at least one mutable attribute in the prediction request using the neural network.
The invention belongs to the technical field of pharmaceutical preparations, and in particular relates to an aprepitant oral liquid preparation and a preparation manufacturing method thereof. 100ml of aprepitant oral liquid comprises 0.50g of aprepitant, 5.00g to 15.00g of solvent, 0.10g to 1.00g of pH regulator, 8.00g to 10.00g of sodium dodecyl sulfate, 3.00g to 5.00g of hydroxypropyl-beta-cyclodextrin, 0.01g to 0.10g of complexing agent and water. The solvent is ethanol, and the complexing agent is disodium edentate. The components are mutually matched to form uniform solution; the medicine is uniformly dispersed in the system, has strong stability, and does not influence the drug effect even if the sweetener such as sucrose is added. Aprepitant in the oral solution is taken as an active ingredient to be uniformly dispersed in the oral solution, the administration dosage can be accurately controlled, excessive treatment or insufficient treatment is avoided, and the administration difficulty of infants is reduced. The oral solution preparation can be released in vitro for 5min to 100%, has a faster release speed than the capsule after being taken, and is beneficial to quick absorption in vivo. The preparation method provided by the invention has the advantages of simple process, short flow, good uniformity of the obtained preparation and low cost, and is suitable for commercial production.
The subsides of well drug paste medicine relate to an outer medicine applying plaster, especially relate to a from mixing subsides of wherein drug paste medicine. The utility model provides a from mixing subsides of wherein drug paste medicine. The problem of the tradition paste medicine applying plaster that is used for the subsides of human acupuncture point to apply be difficult for the technique of long -term storage is solved. It is proper motion hybrid modulation easily, can the long -term storage. Medicine applying plaster is a two -layer structure: the top layer is sealed rete, and the bottom is fixed bed course, be provided with medicine powder cavity and excipient cavity between two -layer. Be provided with the connected chamber passageway that one and two cavities all are linked together between medicine powder cavity and the excipient cavity, still be provided with a vertical isolation bolt slide groove who intersects and pass the connected chamber passageway between medicine powder cavity and the excipient cavity. The stopper has a shape and size to tie with the corresponding isolation of isolation bolt slide groove in keeping apart bolt slide groove, and top salient in seal membrane is tied in the isolation. Still be provided with a line of weakness on the seal membrane.
Helicobacter pylori is a leading cause of gastric mucosal inflammation, peptic ulcers, and gastric adenocarcinoma. Emerging antimicrobial-resistant H. pylori has hampered the successful eradication of frequent chronic infections. Additionally, due to the absence of effective vaccines against H. pylori, a safe vaccine is highly demanded. Disclosed herein are innovative Protective Immunity Enhanced Salmonella Vaccine (PIESV) vector strains to deliver and express multiple H. pylori antigen genes Immunization of mice with a vaccine delivering the HpaA, NapA (also termed Hp-NAP), UreA and UreB antigens, provided sterile protection against H. pylori SS1 infection in 7 out of 10 tested mice. Compared to the control groups that had received PBS or a PIESV with an empty vector, immunized mice exhibited specific and significant cellular recall responses and antigen-specific IgG2c, IgG1, total IgG and gastric IgA antibody titers. Importantly, the mice immunized with the vaccine candidate showed a significant reduction in a load of an unidentified Gram-positive rod-shaped bacteria in their stomach compared to the control groups. In conclusion, a Salmonella Typhimurium-based live vaccine delivering four antigens shows promise as a safe and effective vaccine against H. pylori infection.
All healthy control subjects, 6 couple pairs (12 subjects) healthy controls in which neither member has Parkinson's Disease will receive a baseline and follow up FDOPA PET scan. All subjects will be asked to complete the surveys. The control group will receive training materials in the practice of OM which the couple will be asked to practice for the next 2-3 months. The couple-pair will begin the OM practice initially (in between the baseline and follow up scans. FDOPA scans and surveys will be conducted with both members of the couple pair at approximately 2-3 months.
Provided are a machine learning system and method, an integration server, an information processing device, a program, and an inference model preparation method, with each of which it is possible to suppress bias in training data in federated learning so as to suppress bias in model inference precision. This integration server receives input that specifies a data search option and transmits the specified search option to a plurality of client terminals. Each client terminal searches within a medical facility system to which the client terminal belongs, and transmits, to the integration server, the total number of pieces of data that match the search option. The integration server receives input that specifies the number of pieces of necessary training data and, on the basis of the specified number and the received total number, allocates respective numbers of pieces of training data to be used for learning in the client terminals. According to the specified type and number of pieces of training data, each client terminal uses the data within the medical facility system to perform machine learning for a local model to be trained, and transmits the learning result to the integration server. The integration server integrates the received learning results and updates a master model.
Participants will be assigned to a eating intervention that combines general mindfulness (via headspace) with motivational interviewing for mindful eating They will be asked to attend an online counseling session along with three 10-minute booster phone calls. They will be asked to engage with a digital-based mindful eating program once per week over the course of 8 weeks. In addition, participants will have access to optional educational materials on mindful eating and an optional online private support forum after the intervention period is finished.
1. Process for the industrial synthesis of the compounds of formula (I) wherein R represents a linear or branched (C1-C6)alkyl group, optically clear form, characterized in that alanine of formula (III): is condensed with a compound of formula (IV): wherein R is as defined for formula (I), with hydrogenation catalyzed by 5% palladium-on-carbon, in water, at a pressure of from 1 to 30 bar, at a temperature of from 10 to 60 degree C., in the presence of sodium hydroxide in an amount of from 0 to 0.5 mol per mol of compound of formula (IV) employed, in order to yield the compound of formula (I) in optically pure form following acidification of the reaction mixture to a pH of from 3 to 3.5, filtration, and recrystallization of the resulting precipitate from acetonitrile. 2. Synthesising process according to claim 1 that allows the compound of formula (I) wherein R represents an ethyl group to be obtained. 3. Synthesising process according to either claim 1 or claim 2, characterized in that the hydrogenation pressure is from 1 to 5 bar. 4. Synthesising process according to any one of claims 1 to 3, characterized in that the hydrogenation temperature is from 10 to 40 degree C. 5. Synthesising process according to any one of claims 1 to 4, characterized in that the amount of sodium hydroxide added is from 0.1 to 0.2 mol per mol of the compound of formula (IV) employed. 6. Use of a compound of formula (I) obtained according to any one of claims 1 to 5 in the synthesis of perindopril or pharmaceutically acceptable salts thereof.
Neural mobilization and standardized exercise . 12 sessions over 4 weeks (3 sessions per week).
BACKGROUND: Although radical surgical resection is the most effective treatment for hepatocellular carcinoma (HCC), the high rate of postoperative recurrence remains a major challenge, especially in patients with alpha-fetoprotein (AFP)-negative HCC who lack effective biomarkers for postoperative recurrence surveillance. Emerging radiomics can reveal subtle structural changes in tumors by analyzing preoperative contrast-enhanced computer tomography (CECT) imaging data and may provide new ways to predict early recurrence (recurrence within 2 years) in AFP-negative HCC. In this study, we propose to develop a radiomics model based on preoperative CECT to predict the risk of early recurrence after surgery in AFP-negative HCC.
PATIENTS AND METHODS: Patients with AFP-negative HCC who underwent radical resection were included in this study. A computerized tool was used to extract radiomic features from the tumor region of interest (ROI), select the best radiographic features associated with patient's postoperative recurrence, and use them to construct the radiomics score (RadScore), which was then combined with clinical and follow-up information to comprehensively evaluate the reliability of the model.
RESULTS: A total of 148 patients with AFP-negative HCC were enrolled in this study, and 1,977 radiographic features were extracted from CECT, 2 of which were the features most associated with recurrence in AFP-negative HCC. They had good predictive ability in both the training and validation cohorts, with an area under the ROC curve (AUC) of 0.709 and 0.764, respectively. Tumor number, microvascular invasion (MVI), AGPR and radiomic features were independent risk factors for early postoperative recurrence in patients with AFP-negative HCC. The AUCs of the integrated model in the training and validation cohorts were 0.793 and 0.791, respectively. The integrated model possessed the clinical value of predicting early postoperative recurrence in patients with AFP-negative HCC according to decision curve analysis, which allowed the classification of patients into subgroups of high-risk and low-risk for early recurrence.
CONCLUSION: The nomogram constructed by combining clinical and imaging features has favorable performance in predicting the probability of early postoperative recurrence in AFP-negative HCC patients, which can help optimize the therapeutic decision-making and prognostic assessment of AFP-negative HCC patients.
PURPOSE: In this pilot study, we investigated the cardiac autonomic activity of coronavirus disease 2019 (COVID-19)-infected hospitalized patients. COVID-19 is characterized by cough, fever, and dyspnea, which in some severe cases can lead to hypoxia, respiratory failure, and shock. Since breathing disorders and pulmonary diseases are tightly linked to autonomic dysfunction, we analyzed the cardiac autonomic activity by measuring the deceleration capacity (DC) in COVID-19 patients.
METHODS: In 14 adults (4 men and 10 women) with a median age of 63.5 years and positive for SARS-CoV-2 by polymerase chain reaction (PCR) with severe symptoms requiring hospital treatment, a high-resolution digital 30 min electrocardiogram (ECG) in Frank leads configuration was performed in a resting supine position within the first 48 h after hospital admission. DC was assessed using validated software and associated with several markers of inflammation and clinical course.
RESULTS: The study revealed a significant association between reduced DC (≤ 2.5 ms) and older age (74 years) in COVID-19 patients, compared to those with a higher DC > 2.5 ms (56.5 years). However, the duration of hospitalization was similar for both groups. There was a nonsignificant trend towards a higher maximum viral load in patients with reduced DC. Further, patients with a DC ≤ 2.5 ms showed higher levels of inflammatory markers such as C-reactive protein (CRP) and procalcitonin (PCT), as well as leukocytosis, compared to patients with a DC > 2.5 ms. Also, the COVID-19-severity marker ferritin was significantly elevated in patients with lower DC. Other markers associated with COVID-19, such as lactate dehydrogenase (LDH) and creatine kinase (CK), exhibited comparable levels in both groups.
CONCLUSIONS: Reduced DC (≤ 2.5 ms) was significantly associated with older age, increased inflammatory markers, and elevated ferritin in patients with COVID-19. These findings suggest that DC might serve as a valuable indicator for predicting the risk of severe inflammation in COVID-19 and possibly complications associated with this disease, such as heart failure. Further studies are needed to confirm these observations and clarify the clinical significance of DC in COVID-19 and other infectious diseases.
This invention provides multivalent ligands which carry or display at least one recognition element (RE), and preferably a plurality of recognition elements, for binding directly or indirectly to cells or other biological particles or more generally by binding to any biological molecule. The multivalent ligands provided can most generally function for binding or targeting to any biological particle or molecule and particularly to targeting of cells or cell types or viruses, for cell aggregation and generally for macromolecular assembly of biological macromoleculares. The multivalent ligands of this invention are generally applicable for creating scaffolds (assemblies) of chemical or biological species, including without limitation, antigens, epitopes, ligand binding groups, ligands for cell receptors (cell surface receptors, transmembrane receptors and cytoplasmic receptors), various macromolecules (nucleic acids, carbohydrates, saccharides, proteins, peptides, etc.). In these scaffolds, the number, spacing, relative positioning and relative orientation of recognition elements can be controlled. Multivalent ligands of this invention can carry or display at least one signal recognition element (SRE), and preferably a plurality of signal recognition elements, and modulate biological responses in biological systems. The invention also relates to methods for aggregating biological particles and macromolecules and for modulating biological response employing the multivalent ligands provided.
The present invention discloses a Chinese medicinal compound for treating hysteromyoma, and a preparation method and a quality control method thereof. The Chinese medicinal compound is mainly prepared from seaweed, Rhizoma Sparganii, Herba Duchesnea Indica, Chinese sage herb, Herba Scutellariae Barbatae and Rhizoma Bistortae, and can be added with Codonopsis pilosula, yam, Fructus Setariae Germinatus and Glycyrrhiza uralensis. The compound can be prepared into various clinically acceptable forms. The preparation method for the Chinese medicinal compound comprises the steps that the seaweed is pulverized for diacolation and extraction; the other raw medicinal materials are added with the residue of the diacolation and then are boiled with water; the supernatant fluid is concentrated and is merged with the diacolation liquid; the mixed liquid is concentrated and dried so that a dry extract powder is obtained; added with adjuvant materials, the dry extract powder is prepared into various forms. The quality control method for preparing the Chinese medicinal compound comprises identification with a test solution of nitric acid and silver nitrate or ammonia, identification with Codonopsis pilosula, identification with yam and identification with Glycyrrhiza uralensis. The qualified content, which is determined by the seaweed content (the iodine content) of the daily dose of the Chinese medicinal compound, needs to be at least 0.9 mg.
The present invention relates to compositions based on: (a) a glycosaminoglycan or mixtures thereof;(b) one or more tocopherols, tocotrienols and mixtures thereof; (c) a selected stabilizer. The composition is in solution form, with the above agents being present within specific concentration ranges, without being engaged in formal chemical binding with each other. The component (a) can be e.g. hyaluronic acid (HA) or a salt thereof; the component (b) can be a polyether clathratee.g. a cyclodextrin, or a combination of a fatty acid with an emulsifier; the component (c) can be one or more among α- tocopherols, β-tocopherols, γ-tocopherols, δ-tocopherols; α-tocotrienols, β-tocotrienols, γ-tocotrienols, δ-tocotrienols; preferably the component (c) is vitamin E. In the present compositions, the above agents strongly cooperate to provide enhanced and more stable viscoelastic properties, resulting in a product with higher resistant to thermal treatments like e.g. heat-sterilization, autoclaving, etc. The present compositions, optionally loaded with pharmaceutically and/or cosmetically active agents, are advantageously used in medical or cosmetic methods.
Undergoing IVF treatment often results in the production of more embryos than can safely be transferred at one time. These extra embryos are often cryopreserved for future use. In the event that a couple decides that they do not want to proceed with using cryopreserved embryos, these embryos can be discarded, donated to another couple, or donated to research.

Embryos that are donated to research are used to identify a group of parameters that have significant predictive value for assisted reproductive technology outcomes. We hope to develop future laboratory techniques as we gain a better knowledge of gamete development, fertilization and implantation. We will test, standardize and implement better methods for freezing embryos prior to employing these techniques in a clinical setting. We hope to develop new methods to optimize the determination of genes and chromosomes in embryos. We will test the proficiency of laboratory staff on techniques and/or procedures done in the IVF laboratory. This study WILL NOT:create embryos for research, transfer embryos to an individual, develop cell lines or clones.
Described herein are methods and medicaments useful for treating peritoneal carcinomatosis by administering anti-CTGF agents, particularly anti-CTGF antibodies. Methods for prognosing individuals with perinoteal carcinomatosis are also provided. In one aspect, the present invention provides a method of treating a subject with peritoneal carcinomatosis, the method comprises the administration to the subject of an effective amount ohm anti-connective tissue growth factor (CTGF) agent, thereby treating the peritoneal carcinomatosis. In some embodiments, the peritoneal carcinomatosis results from a cancer selected from the group consisting of gall bladder cancer, bile duct cancer, liver cancer, colon cancer, cancer of the appendix, ovarian cancer, fallopian tube cancer, bladder cancer, pancreatic cancer, mesothelioma, rectal cancer, small bowel cancer and stomach cancer. In particular embodiments, the cancer is ovarian cancer. In further embodiments, the ovarian cancer is classified as serous, clear cell, mucinous or endometrioid.
BACKGROUND: The prevalence of sacroiliac joint pain (SIJP) is estimated to be 10-30% in patients with chronic low back pain. Numerous conservative and surgical treatment modalities for SIJP have been described with limited evidence regarding long-term pain relief. Spinal cord stimulation (SCS) is a well-established technique to treat patients with chronic low back pain. However, the effect on patients with SIJP is not consistent. Therefore, peripheral nerve stimulation (PNS) for chronic SIJP was implemented in experimental trials. Clinical data on PNS for SIJP is still lacking. The authors present a case series and a protocol for a prospective, multicenter study to determine the effect of PNS in patients with chronic intractable SIJP.
METHOD: A multicenter, prospective randomized controlled trial was designed. Patients with chronic intractable SIJP will be recruited and randomized in a 4:3 ratio to either the peripheral nerve stimulation group or to the best medical treatment group. A total of 90 patients are planned to be enrolled (52 in the PNS group and 38 in the BMT group). Patients in the intervention group receive a percutaneous implantation of a unilateral or bilateral lead which is externalized for a trial phase for 3-14 days. After trial phase only patients with at least 50% reduction of pain receive an impulse generator for permanent stimulation. Regular visits for participants are planned on day 0, after 3 months (± 30 days), 6 months (± 30 days), and 12 months (± 60 days). The primary outcome measurements is the difference in Numeric Pain Rating Scale (NRS) between baseline and after 6 months. Secondary outcomes is improvement of pain associated disability (ODI) and improvement of health-related quality of life after 6 and 12 months.
DISCUSSION: We have described the protocol for a prospective, multicenter, randomized trial evaluating the influence of PNS on patients with chronic sacroiliac joint syndrome. We believe that PNS on patients with chronic sacroiliac joint syndrome will show promising results regarding pain relief and quality of life in comparison to BMT after 12 months. The design of this trial promises high evidence in comparison to the data to date.
TRIAL REGISTRATION: ClinicalTrials.gov, NCT05357300. Registered on April 26, 2022.